230 related articles for article (PubMed ID: 19639315)
1. Fotemustine and recurrent glioblastoma: possible new opportunities for an old drug.
Addeo R; De Santi MS; Del Prete S; Caraglia M
Cancer Chemother Pharmacol; 2009 Oct; 64(5):863-6. PubMed ID: 19639315
[No Abstract] [Full Text] [Related]
2. [Fotemustine (Muphoran) in 22 patients with relapses of high-grade cerebral gliomas].
Malhaire JP; Lucas B; Simon H; Person H; Dam-Hieu P; Labat JP
Bull Cancer; 1999 Mar; 86(3):289-94. PubMed ID: 10210763
[TBL] [Abstract][Full Text] [Related]
3. Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation.
Fabi A; Metro G; Russillo M; Vidiri A; Carapella CM; Maschio M; Cognetti F; Jandolo B; Mirri MA; Sperduti I; Telera S; Carosi M; Pace A
BMC Cancer; 2009 Mar; 9():101. PubMed ID: 19335893
[TBL] [Abstract][Full Text] [Related]
4. Low-dose fotemustine as second-line chemotherapy for recurrent glioblastoma multiforme.
De Felice F; Bulzonetti N; Musio D; D'Elia A; Salvati M; Tombolini V
Anticancer Res; 2013 Sep; 33(9):4013-6. PubMed ID: 24023343
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology).
Soffietti R; Trevisan E; Bertero L; Cassoni P; Morra I; Fabrini MG; Pasqualetti F; Lolli I; Castiglione A; Ciccone G; Rudà R
J Neurooncol; 2014 Feb; 116(3):533-41. PubMed ID: 24293233
[TBL] [Abstract][Full Text] [Related]
6. [Clinical significance of mustoforan in management of malignant glioma].
Kobiakov GL
Vopr Onkol; 2007; 53(6):724-9. PubMed ID: 18416147
[No Abstract] [Full Text] [Related]
7. A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma.
Fabrini MG; Silvano G; Lolli I; Perrone F; Marsella A; Scotti V; Cionini L
J Neurooncol; 2009 Mar; 92(1):79-86. PubMed ID: 19018476
[TBL] [Abstract][Full Text] [Related]
8. Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT.
Christmann M; Pick M; Lage H; Schadendorf D; Kaina B
Int J Cancer; 2001 Apr; 92(1):123-9. PubMed ID: 11279615
[TBL] [Abstract][Full Text] [Related]
9. Lecture: fotemustine in brain tumors.
Silvani A; Gaviani P; Lamperti E; Botturi A; Ferrari D; Simonetti G; Salmaggi A
Neurol Sci; 2011 Nov; 32 Suppl 2():S255-7. PubMed ID: 21987288
[TBL] [Abstract][Full Text] [Related]
10. Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study.
Fabi A; Metro G; Vidiri A; Lanzetta G; Carosi M; Telera S; Maschio M; Russillo M; Sperduti I; Carapella CM; Cognetti F; Pace A
J Neurooncol; 2010 Nov; 100(2):209-15. PubMed ID: 20352471
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
[TBL] [Abstract][Full Text] [Related]
12. Focus on Fotemustine.
De Rossi A; Rossi L; Laudisi A; Sini V; Toppo L; Marchesi F; Tortorelli G; Leti M; Turriziani M; Aquino A; Bonmassar E; De Vecchis L; Torino F
J Exp Clin Cancer Res; 2006 Dec; 25(4):461-8. PubMed ID: 17310834
[TBL] [Abstract][Full Text] [Related]
13. AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.
Brandes AA; Finocchiaro G; Zagonel V; Reni M; Caserta C; Fabi A; Clavarezza M; Maiello E; Eoli M; Lombardi G; Monteforte M; Proietti E; Agati R; Eusebi V; Franceschi E
Neuro Oncol; 2016 Sep; 18(9):1304-12. PubMed ID: 26951379
[TBL] [Abstract][Full Text] [Related]
14. [Chemotherapy of brain tumors: biological basis of its limited efficacy].
Mousseau M
Bull Cancer; 1994 May; 81(5):414-24. PubMed ID: 7749219
[TBL] [Abstract][Full Text] [Related]
15. Effective combined immunochemotherapy with dinitrochlorobenzene and fotemustine in skin and brain metastases of melanoma.
Göring HD; Zierner A; Kröning Y; Trebing D; Kämpgen E; Bröcker EB
Melanoma Res; 1998 Aug; 8(4):379. PubMed ID: 9764815
[No Abstract] [Full Text] [Related]
16. Safety of second-line chemotherapy with non-conventional fotemustine schedule in recurrent high grade gliomas: a single institution experience.
Gaviani P; Simonetti G; Salmaggi A; Lamperti E; Silvani A
J Neurooncol; 2013 Jul; 113(3):527-9. PubMed ID: 23703296
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma.
Santoni M; Scoccianti S; Lolli I; Fabrini MG; Silvano G; Detti B; Perrone F; Savio G; Iacovelli R; Burattini L; Berardi R; Cascinu S
J Neurooncol; 2013 Jul; 113(3):397-401. PubMed ID: 23564276
[TBL] [Abstract][Full Text] [Related]
18. The combination of carmustine wafers and fotemustine in recurrent glioblastoma patients: a monoinstitutional experience.
Lombardi G; Della Puppa A; Zustovich F; Pambuku A; Farina P; Fiduccia P; Roma A; Zagonel V
Biomed Res Int; 2014; 2014():678191. PubMed ID: 24812626
[TBL] [Abstract][Full Text] [Related]
19. [Evolution of chemotherapy for malignant brain tumors].
Takeshima H; Kuratsu J
No Shinkei Geka; 2003 Jul; 31(7):725-34. PubMed ID: 12884787
[No Abstract] [Full Text] [Related]
20. GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status.
Pérez-Segura P; Manneh R; Ceballos I; García A; Benavides M; Fuster J; Vaz MA; Cano JM; Berros JP; Covela M; Moreno V; Quintanar T; García Bueno JM; Fernández I; Sepúlveda J
Clin Transl Oncol; 2016 Aug; 18(8):805-12. PubMed ID: 26542177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
